REG - N4 Pharma PLC - Technology Transfer and Manufacturing Contract

N4 PharmaAnnouncement

01/09/2020 07:01

RNS Number : 5453X
  
N4 Pharma PLC
  
01 September 2020
  
 

1 September 2020
 
N4 Pharma plc
 
("N4 Pharma" or the "Company")
 
Technology Transfer and Manufacturing Contract
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, announces that it has appointed the API and Nanomedicines business unit of Ardena ('Ardena') as its contract development and manufacturing organisation ('CDMO') partner for the technology transfer and upscaling manufacture of Nuvec®.
The contract is divided into three stages:
1.    Establishing an understanding of the current manufacture process, scale-up and analysis of the transfer of technology;
2.    Process optimisation and scale-up resulting in the manufacture and analysis of a non-GMP 50g batch of Nuvec®;
3.    Manufacture, testing and product certification of Nuvec® for GMP status
 
The manufacture will initially be for the fundamental "naked" Nuvec® silica nanoparticles albeit Ardena has the ability to produce functionalised particles as may be required by the Company or any collaborators from time to time.
 
Ardena is a CDMO based in the Netherlands with substance and drug product manufacturing capability and is experienced in the manufacture of nanoparticles (liposomes, PLGA micro and nanospheres, silica nanoparticle) which is of particular relevance for Nuvec®. Ardena also has a GMP manufacturing, analytical and product release capability.
 
Nigel Theobald, Chief Executive Officer, commented: "We are delighted to be working with Ardena as our tech transfer and manufacturing partner. As we look to continue the advancement of Nuvec® and its applications it is increasingly important that we have access to a consistent Nuvec® product across our studies together with the potential to move to GMP certification as and when required and Ardena can provide this."
 
Enquiries:
 



N4 Pharma plc








Nigel Theobald, CEO 


Via IFC Advisory




Luke Cairns, Executive Director


















SP Angel Corporate Finance LLP


Tel: +44(0)20 3470 0470




Nominated Adviser and Joint Broker








Matthew Johnson/Caroline Rowe (Corporate Finance)








Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)


















Turner Pope Investments (TPI) Limited


Tel: +44(0)20 3657 0050




Joint Broker








Andy Thacker


















IFC Advisory Ltd
Financial PR
Graham Herring
Zach Cohen                                                  


Tel: +44(0)20 3934 6630



 
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
CNTEAPPFDAFEEFA